Dulaglutide

Generic Name: Dulaglutide

Brand Names: Trulicity

Drug Type: Biotech

CAS Number: 923950-08-7

Unique Ingredient Identifier: WTT295HSY5

Background: Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.

Indication: Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Associated Conditions: Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus

Clinical Trials

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: LY3457263
Drug: Dulaglutide

First Posted Date: 2022-05-17

Last Posted Date: 2024-01-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 94

Registration Number: NCT05377333

Locations: 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
CenExel-HRI, Berlin, New Jersey, United States
🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States

and more 2 locations

Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease

Phase 2

Completed

Conditions: Chronic Kidney Diseases

Interventions: Drug: dulaglutide injection

First Posted Date: 2022-02-24

Last Posted Date: 2025-04-20

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 7

Registration Number: NCT05254418

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Basal Plus GLP1-ra on Glycemic Variability in CKD

Phase 4

Completed

Conditions: Diabetic Kidney Disease
Diabetes Mellitus

Interventions: Drug: Dulaglutide
Drug: Insulin Degludec
Device: Continuous glucose monitor

First Posted Date: 2022-02-01

Last Posted Date: 2024-12-03

Lead Sponsor: Elaine Chow

Target Recruit Count: 95

Registration Number: NCT05218915

Locations: 🇭🇰
Prince of Wales Hospital, Sha Tin, Hong Kong

Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

Phase 4

Not yet recruiting

Conditions: Metabolic-associated Fatty Liver Disease
Type 2 Diabetes

Interventions: Drug: Empagliflozin
Drug: Dulaglutide
Drug: Empagliflozin and Dulaglutide

First Posted Date: 2021-12-01

Last Posted Date: 2022-10-04

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 135

Registration Number: NCT05140694

A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: LY3502970
Drug: Dulaglutide
Drug: Placebo

First Posted Date: 2021-09-17

Last Posted Date: 2023-10-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 383

Registration Number: NCT05048719

Locations: 🇸🇰
MEDI-DIA s.r.o., Sabinov, Prešovský Kraj, Slovakia
🇸🇰
Funkystuff, Nove Zamky, Slovakia
🇺🇸
Cotton O'Neil Clinical Research Center, Topeka, Kansas, United States

and more 41 locations

The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

Phase 4

Recruiting

Conditions: Diabetes Mellitus, Type 2
Overweight or Obesity

Interventions: Drug: Beinaglutide
Drug: Dulaglutide

First Posted Date: 2021-08-13

Last Posted Date: 2023-03-17

Lead Sponsor: Second Xiangya Hospital of Central South University

Target Recruit Count: 120

Registration Number: NCT05005741

Locations: 🇨🇳
The First Affiliated Hospital of Harbin Medical University, Ha'erbin, Heilongjiang, China
🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

and more 1 locations

Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

Phase 4

Conditions: Type 2 Diabetes Mellitus
Glucose, High Blood

Interventions: Drug: IGlarLixi
Drug: Dulaglutide

First Posted Date: 2021-05-19

Last Posted Date: 2022-07-20

Lead Sponsor: Chungbuk National University Hospital

Target Recruit Count: 40

Registration Number: NCT04893148

Locations: 🇰🇷
Chungbuk National University Hospital, Cheonju, Chungcheongbuk-do, Korea, Republic of

A Study of LY3437943 in Participants With Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: LY3437943
Drug: Placebo
Drug: Dulaglutide

First Posted Date: 2021-04-30

Last Posted Date: 2023-07-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 281

Registration Number: NCT04867785

Locations: 🇺🇸
Humphreys Diabetes Center, Boise, Idaho, United States
🇺🇸
Logan Health Research, Kalispell, Montana, United States
🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States

and more 37 locations